Financial Results for the quarter and nine months ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.1 pts more than Nifty Microcap 250 and 6.6 pts more than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On a standalone basis, Relic Technologies reported total income of Rs. 35.04 lakhs in Q3 FY26 (vs Rs. 49.83 lakhs in Q3 FY25) and a net profit of Rs. 17.38 lakhs (vs a loss of Rs. 151.23 lakhs). For 9M FY26, total income fell sharply to Rs. 92.76 lakhs from Rs. 159.57 lakhs, but the company swung to a net profit of Rs. 44.71 lakhs from a loss of Rs. 147.49 lakhs. Standalone revenue from operations is zero — the planned shift to pharma and wellness products has not yet started, as the company is still waiting for regulatory permissions. On a consolidated basis, 9M FY26 results worsened significantly: net loss of Rs. 400.79 lakhs (vs Rs. 96.08 lakhs loss a year ago) on total income of Rs. 275.60 lakhs, driven by heavy losses at subsidiaries Relic Pharma Ltd and Truhealthy Wellness Pvt Ltd (combined 9M pre-tax loss of Rs. 414.32 lakhs). An exceptional item of Rs. 232.12 lakhs was recorded in the prior quarter. The auditor (D. Kothary & Co.) issued an unmodified limited review opinion. Paid-up equity capital rose to Rs. 559.12 lakhs after conversion of 4,41,164 warrants.
Shareholders should note the divergence between standalone and consolidated books: standalone profits come entirely from other income with no operating revenue, while consolidated results are deeply loss-making due to subsidiaries. The deferred tax asset recognition relies on management's confidence in future profits, which adds risk. Stock price impact is likely muted given the very small scale and pending business transition.